ReviewAdvances in therapy2026
Clinical Relevance of Bile Acid and Bile Acid-Related Therapy in Liver Cirrhosis: A Review.
Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cirrhosis, the end stage of various chronic liver diseases, is characterized by complex pathophysiologies and poor outcomes. Recently, dysregulation of bile acid metabolism has been increasingly recognized as a key factor in the development and progression of liver cirrhosis and decompensation. Total bile acid (TBA) levels are often elevated in patients with liver cirrhosis and are associated with hepatic dysfunction, severity of fibrosis, and specific clinical outcomes, including hepatocellular carcinoma, acute-on-chronic liver failure, hepatic encephalopathy, and short-term survival or mortality. Therefore, bile acid, particularly total bile acid, may serve as potential biomarkers for evaluating the severity, progression, and prognosis of liver cirrhosis. This paper aims to review the biosynthesis and metabolic mechanisms of bile acid, as well as their characteristic changes in viral, cholestatic, alcoholic, and metabolic dysfunction-associated steatotic liver disease, and discuss the impact of bile acid in the assessment of hepatocellular carcinoma, acute-on-chronic liver failure, and other hepatic decompensation events. Meanwhile, recent advances in bile acid-related therapeutic strategies and their potential application in liver cirrhosis are briefly summarized.Infographic available for this article https://doi.org/10.6084/m9.figshare.32716986 . INFOGRAPHIC.
Indexed as
Identifiers
42554950What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.